Skip to main content

Advertisement

SpringerLink
Log in

CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med 2006; 355: 2408–2417.

    Article  CAS  Google Scholar 

  2. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.

    Article  CAS  Google Scholar 

  3. Rosti G, Martinelli G, Bassi S, Amabile M, Tra bachi E, Giannini B et al. Molecular response to Imatinib in late chronic phase chronic myeloid leukemia. Blood 2004; 103: 2284–2290.

    Article  CAS  Google Scholar 

  4. Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL . Punish the parent not the progeny. Blood 2005; 105: 1862–1866.

    Article  CAS  Google Scholar 

  5. Cortes J, O'Brien S, Kantarjian H . Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204–2205.

    Article  CAS  Google Scholar 

  6. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60.

    Article  CAS  Google Scholar 

  7. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701–4707.

    Article  CAS  Google Scholar 

  8. Goldman J, Gordon M . Why do chronic myelogenous leukemia stem cells survive allogeneic stem celltransplantation or imatinib: does it really matter? Leuk Lymphoma 2006; 47: 1–7.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from PAR 2005, MIUR 2005, SIENAIL, Fondazione Monte dei Paschi. Informed consent was obtained from patients before entering into the study. M Bocchia designed research, analyzed data and wrote the paper. M Ippoliti performed research and analyzed data. A Gozzetti analyzed data and contributed in writing the manuscript. E Abruzzese contributed in designing the research and analyzing data. S Calabrese, R Crupi, D Tozzuoli, M Amabile and G Martinelli contributed in performing research. MM Trawinska, M Defina and MT Pirrotta collected and managed the clinical data. F Lauria supervised the research and revised the manuscript.

Author information

Authors and Affiliations

  1. Department of Hematology, Siena University, Siena, Italy

    M Bocchia, M Ippoliti, A Gozzetti, S Calabrese, M T Pirrotta, R Crupi, D Tozzuoli, M Defina & F Lauria

  2. Department of Hematology, Roma Tor Vergata University, Roma, Italy

    E Abruzzese & M M Trawinska

  3. Hematology and Clinic Oncology ‘Seragnoli’ Institute, Bologna University, Bologna, Italy

    M Amabile & G Martinelli

Authors
  1. M Bocchia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Ippoliti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Gozzetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Abruzzese
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Calabrese
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Amabile
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M T Pirrotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Crupi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D Tozzuoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M M Trawinska
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Defina
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. G Martinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. F Lauria
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Bocchia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bocchia, M., Ippoliti, M., Gozzetti, A. et al. CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. Leukemia 22, 426–428 (2008). https://doi.org/10.1038/sj.leu.2404893

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404893

  • Springer Nature Limited

This article is cited by

Search

Navigation